Intelligene Inc. (TPEX:7832)

Taiwan · Delayed Price · Currency is TWD

13.35

-0.05 (-0.37%)

At close: Apr 27, 2026

178.13% (1Y)

Market Cap	7.74B
Revenue (ttm)	2.39M
Net Income (ttm)	-148.61M
Shares Out	580.00M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,090
Average Volume	274,431
Open	13.30
Previous Close	13.40
Day's Range	13.20 - 13.65
52-Week Range	4.73 - 17.65
Beta	n/a
RSI	45.14
Earnings Date	Apr 24, 2026

About Intelligene

Intelligene Inc. engages in the research and development of RNA gene therapy drugs in Taiwan and Australia. The company offers IG-001, a siRNA-based drug which is under preclinical trials for the treatment of coronavirus disease; and IG-002, a siRNA-based drug which is under drug screening for the treatment of influenza. It also provides lipid nanoparticle and exosome drug encapsulation technologies to customize drug carriers and develop nucleic acid therapeutics. The company was founded in 2023 and is based in Taipei, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2023

Employees 20

Stock Exchange Taipei Exchange

Ticker Symbol 7832

Full Company Profile

Financial Performance

In 2025, Intelligene's revenue was 2.39 million, a decrease of -48.99% compared to the previous year's 4.68 million. Losses were -148.61 million, 4.55% more than in 2024.

Financial Statements

News

There is no news available yet.